ERBB2 and metastatic neoplasm: Thus, to extend clinical benefit of HER2-targeted therapies to other HER2-expressing solid tumors, and to treat patients with recurrent or metastatic disease that have progressed after standard of care therapy, there is a need for novel anti-HER2 therapies that have greater antitumor activity and differentiated mechanisms of action (MOA)3.